PIK3CA somatic mutation status in relation to patient and tumor factors in racial/ethnic minorities with colorectal cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 7, 2015, Pages 1046-1051

  Phipps, Amanda I ^a,b   Ahnen, Dennis J ^c,d   Cheng, Iona ^e   Newcomb, Polly A ^a,b   Win, Aung Ko ^f   Burnett, Terrilea ^g  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF HAWAII CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOINOSITIDE 3 KINASE CATALYTIC ALPHA POLYPEPTIDE; UNCLASSIFIED DRUG; DNA; PIK3CA PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; ASCENDING COLON; CANCER GROWTH; CANCER REGISTRY; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; ETHNIC GROUP; EXON; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; SOMATIC MUTATION; CANCER STAGING; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; HEALTH; INCIDENCE; METABOLISM; MIDDLE AGED; MINORITY GROUP; MULTICENTER STUDY; MUTATION; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; GLOBAL HEALTH; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MINORITY GROUPS; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; SEER PROGRAM; UNITED STATES; YOUNG ADULT;

EID: 84941772770     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0204     Document Type: Article

References (33)

1. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74.
2. Chong ML, Loh M, Thakkar B, Pang B, Iacopetta B, Soong R. Phosphatidylinositol-3-kinase pathway aberrations in gastric and colorectal cancer: meta-analysis, co-occurrence and ethnic variation. Int J Cancer 2014;134: 1232-8.
3. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle 2004;3:1221-4.
4. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-41.
5. Liao X, Morikawa T, Lochhead P, Imamura Y, Kuchiba A, Yamauchi M, et al. Prognostic role of PIK3CA mutation in colorectal cancer: cohort study and literature review. Clin Cancer Res 2012;18:2257-68.
6. Whitehall VL, Rickman C, Bond CE, Ramsnes I, Greco SA, Umapathy A, et al. Oncogenic PIK3CA mutations in colorectal cancers and polyps. Int J Cancer 2012;131:813-20.
7. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 2009;27:1477-84.
8. Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S Jr., et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41:1649-54.
9. Day FL, Jorissen RN, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin Cancer Res 2013;19:3285-96.
10. Abubaker J, Bavi P, Al-Harbi S, Ibrahim M, Siraj AK, Al-Sanea N, et al. Clinicopathological analysis of colorectal cancers with PIK3CA mutations in Middle Eastern population. Oncogene 2008;27:3539-45.
11. Zhu YF, Yu BH, Li DL, Ke HL, Guo XZ, Xiao XY. PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol 2012;18:3745-51.
12. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-typemetastatic colorectal cancer: A systematic review andmetaanalysis. Ann Oncol 2012;23:1518-25.
13. Phipps AI, Makar KW, Newcomb PA. Descriptive profile of PIK3CAmutated colorectal cancer in postmenopausal women. Int J Colorectal Dis 2013;28:1637-42.
14. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractorymetastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 2010;11:753-62.
15. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367:1596-606.
16. Shen Y, Wang J, Han X, Yang H, Wang S, Lin D, et al. Effectors of epidermal growth factor receptor pathway: The genetic profiling of KRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine. PLoS One 2013;8:e81628.
17. Kang M, Shen XJ, Kim S, Araujo-Perez F, Galanko JA, Martin CF, et al. Somatic genemutations in African Americansmay predict worse outcomes in colorectal cancer. Cancer Biomark 2013;13:359-66.
18. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: An international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2331-43.
19. Coloncfr.org [Internet]. Cancer Family Registries Informatics Support Center [updated 2015; cited March 30, 2015]. Available from: http://coloncfr.org.
20. Ligresti G, Militello L, Steelman LS, Cavallaro A, Basile F, Nicoletti F, et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 2009;8:1352-8.
21. Baker CL, Vaughn CP, Samowitz WS. A PIK3CA pyrosequencingbased assay that excludes pseudogene interference. J Mol Diagn 2012; 14:56-60.
22. Buchanan DD, Sweet K, Drini M, JenkinsMA, Win AK, English DR, et al. Risk factors for colorectal cancer in patients with multiple serrated polyps: A cross-sectional case series from genetics clinics. PLoS One 2010;5:e11636.
23. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
24. Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20: 1043-8.
25. Cicek MS, Lindor NM, Gallinger S, Bapat B, Hopper JL, Jenkins MA, et al. Quality assessment and correlation ofmicrosatellite instability and immunohistochemical markers among population- And clinic-based colorectal tumors results from the Colon Cancer Family Registry. J Mol Diagn 2011; 13:271-81.
26. World Health Organization. International classification of diseases for oncology. Geneva: WHO; 2000.
27. Therneau TM, Grambsch PM. Modeling survival data: Extending the Cox model. New York: Springer; 2000.
28. Lin XF, Shi KQ, You J, Liu WY, Luo YW, Wu FL, et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: A large study. Mol Biol Rep 2014;41:2989-97.
29. Tong L, Yang XX, Liu MF, Yao GY, Dong JY, Ye CS, et al. Mutational analysis of key EGFR pathway genes in Chinese breast cancer patients. Asian Pac J Cancer Prev 2012;13:5599-603.
30. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 2007;121:1771-8.
31. Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, et al. Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 2013;105: 1789-98.
32. Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol 2013;31:4297-305.
33. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50:113-30.